After chemoradiotherapy for unresectable oesophageal SCC, atezolizumab plus tiragolumab did not improve PFS (HR 0.82) or OS (HR 0.91) vs placebo, missing the primary endpoint. Atezolizumab alone had longer OS (HR 0.69; descriptive P). Treatment-related AEs: 74.8%, 65.2%, 55.4%.
RCTn = 760
Xu et al. Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study